Online ISSN: 2515-8260

Keywords : Cost Effective Ratio (CER)

A study on pharmacoeconomics analysis of antihypertensive drugs

Dr. Syed Sujat Pasha,Dr.Sha NaseeruddinMakandar, Dr.Lakshmipathi BS

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 951-957

Hypertension is one of the leading cause of global burden of diseases and as it is a chronic
condition with significant detrimental effects on the wide range of health outcomes, cost
effective management of hypertension appears to be a great challenge for both developed as
well as developing countries. Even though recently there have been lot of studies on
pharmacoeconomics and outcome research in the field of hypertension globally, but the
results cannot be exactly extrapolated to Indian scenario as the economic status and
socioeconomic factors are different in India as compared to the countries. Hence a study was
undertaken to evaluate the cost effective antihypertensive drugs in our hospital. An
observational comparative study is planned on 100 patients attending the outpatient
Department of General medicine with a follow up period of 6 months. Written informed
consent is obtained from all the patients satisfying the inclusion criteria. Multitherapy was
frequently prescribed (74%), out of that Atenolol with Amlong combination was most
common (54%). Diabetes was the most common co-morbid condition (24%). Multitherapy
was most frequently prescribed, and Amlodipine with Enalapril combination proved to be
most cost effective therapy. HRQoL was not much different in all the treatment groups.